Form 4: Seres Therapeutics Executive VP Thomas DesRosier Reports Stock Transactions

Chief Legal Officer and EVP of Seres Therapeutics, Thomas DesRosier, reports the vesting and sale of restricted stock units to cover taxes.

Summary

• Thomas DesRosier, Chief Legal Officer and EVP of Seres Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• The transactions involve the vesting and sale of restricted stock units (RSUs).
• On May 15, 2025, 133 RSUs vested and settled, resulting in the acquisition of 133 shares of common stock.
• Additionally, 111 RSUs vested and settled, resulting in the acquisition of 111 shares of common stock.
• DesRosier sold 79 shares of common stock at a price of $7.28 per share.
• These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 2, 2023, to cover taxes related to the vesting of the RSUs.
• Following these transactions, DesRosier beneficially owns 7,287 shares of common stock, 929 restricted stock units from the first transaction, and 1,224 restricted stock units from the second transaction.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction related to executive compensation and doesn't indicate any significant positive or negative development for the company.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating transparency and avoiding concerns about insider trading.

Future Outlook

The remaining restricted stock units will continue to vest and settle in 12 equal quarterly installments.

Industry Context

Form 4 filings are a routine part of executive compensation and provide transparency into insider transactions. Investors monitor these filings to understand management's perspective on the company's stock.

Comparison to Industry Standards

• Executive compensation packages often include restricted stock units that vest over time.
• The use of Rule 10b5-1 trading plans is a common practice to allow insiders to sell shares without concerns about insider trading.
• Comparable companies in the biotechnology sector, such as Vertex Pharmaceuticals and Biogen, also have executives who regularly file Form 4s related to stock options and RSU vesting.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders.
• Shareholders may view the transactions as part of normal executive compensation.

Key Dates

Keywords

Form 4, Seres Therapeutics, MCRB, Thomas DesRosier, Restricted Stock Units, RSU, Beneficial Ownership, Rule 10b5-1, Vesting, Stock Sale